



# UNITED STATES PATENT AND TRADEMARK OFFICE

*cf*  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/806,022	03/22/2004	Jeffrey S. Kiel	455-024	1967
1009	7590	09/24/2007		
KING & SCHICKLI, PLLC 247 NORTH BROADWAY LEXINGTON, KY 40507			EXAMINER OH, TAYLOR V	
			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			09/24/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

Application No.

10/806,022

Applicant(s)

KIEL ET AL.

Examiner

Taylor Victor Oh

Art Unit

1625

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 23 July 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,2 and 5-21 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,2 and 5-21 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                                | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

Applicant's arguments with respect to claims 1-2, 5-21 have been considered but are moot in view of the new ground(s) of rejection.

### The Status of Claims

Claims 1-2, 5-21 are pending.

Claims 1-2, 5-21 are rejected.

### **DETAILED ACTION**

1. Claims 1-2, 5-21 are under consideration in this Office Action.

#### **Priority**

2. It is noted that this application claims benefit of 60/457,399 (03/25/03).

#### **Drawings**

3. None.

#### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Art Unit: 1625

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 1-2,5-9, and 18-19 provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1,3,5-8,11 of copending Application No. 10/269,027. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claim 1 is related to the process for preparing a gabapentin tannate pharmaceutical composition comprising mixing an anti-clumping agent, tannic acid together to form a reaction mixture; adding gabapentin to said reaction mixture; and adding one or more solvents to said reaction mixture, whereas the claims 1,3 of the copending Application No. 10/269,027 is described below:

1. A process for the conversion of at least one active pharmaceutical ingredient into its tannate salt complex for incorporation into a therapeutic tablet, capsule or other solid dosage form, the process comprising:

(a) combining, in the presence of a pharmaceutically acceptable liquid, the salt or free base of an active pharmaceutical ingredient with tannic acid to form a tannate salt complex of the active pharmaceutical ingredient and without further treatment; and

(b) processing the tannate salt complex into a tablet, capsule or other solid dosage form.

3. The process according to claim 1, wherein the active pharmaceutical ingredient is selected from the group consisting of:

(50) gabapentin

However, the instant invention differs from the copending Application No. in that the gabapentin tannate is not specified in the claim 1.

Even so, claim 3 describes that gabapentin can be one of the active pharmaceutical ingredients to be converted into its complex form with tannate salt. Therefore, it would have been obvious to the skillful artisan in the art to be motivated to rearrange the claims in such a way to emphasize the certain aspect of the claimed invention in the process because they are not patentably distinct from each other with respect to the claims of themselves. Furthermore, it is because claim 1 of the instant invention does fall into the scope of claim 1 in the copending application.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

#### ***Claim Rejections - 35 USC § 103***

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-2, 5-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Patel et al (US 6,248,363) in view of Gordziel (U.S. 6,037,358).

Patel et al discloses the general teachings of converting of one of the active pharmaceutical ingredients (hydrophilic, amphiphilic or hydrophobic) such as gabapentin (see col. 5, line 46) into its tannate salt complex (see col. 40, line 7) as a salt of a pharmaceutically acceptable cation (see col. 39, line 65).

The instant invention, however, differs from the prior art reference in that the claimed reaction temperature range (15 to 150 °C) is not disclosed ; the claimed pH is between 2 to 11; the ratio of tannic acid to gabapentin is unspecified.

Gordziel discloses a process of preparing antihistamine tannates ; for example , chlorpheniramine tannate can be obtained from reacting chlorpheniramine with tannic acid in

Art Unit: 1625

the presence of isopropanol (see col. 1 , lines 64-67). Furthermore, the following example is further exemplified as shown below (see col. 2 , ex. 1):

**EXAMPLE 1**

Ingredient	Milligrams per Tablet
Chlorpheniramine Tannate	9.0
Phenylephrine Tannate	25.0 <sup>1</sup>
Starch, NF	65.0
Methylcellulose, USP	150
Polygalacturonic Acid	32.0
Dibasic Calcium Phosphate, USP, Dihydrate	65.0
Povidone, USP	25.0
Talc, USP	5.4
FD&C Red #40 Aluminum Lake-40%	3.93
D&C Blue #1 Aluminum Lake-29%	1.0
Magnesium Stearate, NF	4.0
Alcohol Specially Denatured 23A 190 Proof	140 <sup>2</sup>

<sup>1</sup>15% excess added during manufacture<sup>2</sup>Not present in finished tablet product

Typically, in the conventional isopropanol route, the decon-  
gestant or antihistaminic free base and the tannic acid will be  
present in the isopropanol at a concentration of about 20%  
based on the weight of the reaction mixture. The reaction  
5 mixture is stirred for about one hour while maintaining the  
mixture at 60-70° C. The reaction mixture is cooled to room  
temperature and then filtered, washed with isopropanol and  
then vacuum dried. Alternative routes to the tannate salts are  
described in U.S. Pat. No. 5,599,846 and U.S. Pat. No.  
10 5,663,415.

With respect to the unspecified ranges of pH, the ratio, the limitation of a process with  
respect to ranges of pH, time , ratio and temperature does not impart patentability to a process  
when such values are those which would be determined by one of ordinary skill in the art in

Art Unit: 1625

achieving optimum operation of the process. Furthermore, the selection of ranges of pH or the ratio is not a patentable modification in the absence of unobvious results. In re Rose, 105 U.S.P.Q. 237 (C.C.P.A. 1955). The pH value and the ratio are well understood by those of ordinary skill in the art to be result-effective variables, especially when attempting to control the reaction process.

Patel et al expressly discloses that it seems reasonable to convert the active pharmaceutical ingredients such as chlorpheniramine (see col. 5, line 34), gabapentin (see col. 5, line 46) into its tannate salt complex. Similarly, Gordziel does teach the process of preparing pure antihistamine tannate compositions by reacting chlorpheniramine with tannic acid in the presence of isopropanol. By comparison, there is an equivalency between chlorpheniramine tannate and gabapentin tannate with respect to preparing the their corresponding tannate pharmaceutical forms between the prior art.

Therefore, if the skilled artisan had desired to convert the active gabapentin pharmaceutical ingredient into its tannate salt complex as an alternative to the chlorpheniramine tannate composition, one skilled in the art would be motivated to incorporate Gordziel's anti-clumping process of preparing the tannate composition into the Patel et al process. This is because the skilled artisan in the art would expect such a combination to be successful in producing gabapentin tannate as the guidance that the active hydrophilic, lipophilic, amphiphilic or hydrophobic ingredient can be solubilized in the encapsulation shown in the Patel et al process.



Art Unit: 1625

Claims 1-2 and 5-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bryans et al (US 7,141,606) in view of Berge et al (J. of Pharmaceutical Sciences, 66,no. 1, Jan, 1977, p.1-19).

Bryans et al discloses gabapentin derivatives having the following uses(see col. 1, lines 22-26 ):

protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

Art Unit: 1625

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

(see col. 12, lines 4-45)

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component. In medical use the drug may be administered three times daily as, for example, capsules of 100 or 300 mg. The composition can, if desired, also contain other compatible therapeutic agents.

(see col. 13, lines 1-7).

Furthermore, the gabapentin has a nitrogen and a carboxyl group in the chemical compound and its salt possible forms are described in the followings (see col. 10, lines 33-37):

Since amino acids are amphoteric, pharmacologically compatible salts when R is hydrogen can be salts of appropriate inorganic or organic acids, for example, hydrochloric, sulphuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, methanesulfonic acid,

However, the instant invention differs from the prior art in that the formation of gabapentin tannate is undisclosed in the prior art.

Berge et al describes potentially useful salts in the pharmaceutical compounds in which the salt is formed by an acid-base reaction involving either a proton-transfer or neutralization reaction (see page 2 , left col. at the middle paragraph). Furthermore the table I shows various FDA-approved commercially marketed salts among which the tannate is displayed as one of the potential candidates for the pharmaceutical compounds.

Bryans et al expressly discloses that it seems reasonable to form the organic salt forms of gabapentin for sleep disorders (see col. 10 ,lines 33-37). Berge et al expressly describes various FDA-approved commercially marketed salts among which the tannate is displayed as one of the potential candidates for the pharmaceutical compounds. Therefore, it would have been obvious to the skillful artisan in the art to be motivated to use the tannate for the salt of gabapentin for sleep disorders ; this is because Berge et al expressly teaches that one of the FDA-approved commercially marketed salts can be the tannate.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taylor Victor Oh whose telephone number is 571-272-0689. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Taylor Victor Oh, MSD,LAC

Primary Examiner

Art Unit : 1625

